Anti-tumor immune response enhancer
AssigneesKenichiro HASUMI, National Center for Child Health and Development
InventorsKenichiro HASUMI, Ko RII
Life of this patent
Estimating the term…
Abstract
The present invention aims to provide means to maintain and enhance the anti-tumor activity of TADC in a tumor microenvironment. The present inventors found that when a composition comprising three kinds of phospholipids “cPLs adjuvant” is administered, the degree of growth of tumors implanted to mice was notably suppressed, and confirmed that immature dendritic cells, when cultured in vitro in the presence of the cPLs adjuvant, become mature bone marrow-derived dendritic cells and induce cytokine production.
Claims11
An anti-tumor immune response enhancer comprising phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine.
Dependencies are inferred from the claim text.